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Abstract
Background
The evaluation of patient-reported health-related quality of life (HRQOL) in pulmonary tuber-
culosis (TB) contributes to a comprehensive understanding of the burden associated with
this disease. The aim of this study was to assess the overall impact of TB on the health sta-
tus and on single health domains identified in the WHO definition of health, including physi-
cal, mental and social health aspects.
Methods
Four instruments for HRQOL evaluation were applied in a longitudinal multicentre study
during six-month standard TB treatment in South Africa. These included the generic
SF-12 and EQ-5D-5L, the disease-specific St. George´s Respiratory Questionnaire
(SGRQ) and the condition-specific Hospital Anxiety and Depression Scale (HADS).
Statistical analysis included significance testing, univariable and multivariable analysis,
and repeated measures ANOVA. Change over time in the physical component score (PCS)
of SF-12 was defined as primary endpoint. A target sample size of 96 patients was
estimated.
Results
HRQOL of the study participants was impaired in all physical, mental and psycho-social
health domains at treatment start. HRQOL improved significantly and in a clinically mean-
ingful manner during the course of standard TB treatment, over the period of the study. The
greatest improvement (95%) was observed in mental health. Younger patients with higher
education and who were employed had a better HRQOL.
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Discussion
This study demonstrates the need for an integrative understanding of TB with HRQOL as
core element to inform gaps in current TB management. Improvements in the management
of TB following an integrative patient-centred approach will contribute towards meeting the
United Nations Sustainable Development Goal 3 (SDG3) target and will support the End TB
strategy of the WHO.
Introduction
At the beginning of 2016, the United Nations (UN) introduced the Sustainable Development
Goals (SDGs) to replace the Millennium Development Goals (MDGs) established in 2000 [1].
The third goal of the SDGs (SGD3) aims to ensure healthy lives and promote well-being at all
ages [1]. One target of SGD3 focuses on universal health coverage, including access to safe,
effective, high quality and affordable essential medicines [2]. Access to medicines requires
sponsors to demonstrate that the medicine is safe, effective and affordable. The evidence of the
real benefit of a treatment is usually evaluated based on clinical trials and real world data evi-
dence. Only after this evidence has been provided, can medicines be made accessible through
healthcare organizations. The World Health Organization (WHO) claims that patient involve-
ment in their healthcare is a social, economic and technical necessity [3]. The evaluation of a
patient-reported perspective of a disease and treatment contributes to a comprehensive under-
standing of the benefit and risk associated with that disease. This is important as some con-
cepts cannot be measured objectively. One specific patient-reported outcome (PRO) is health-
related quality of life (HRQOL). HRQOL is a PRO which refers to the multi-dimensional
nature of health, and usually includes physical, mental and social health domains [4].
A further target of the UN SDG 3 includes an end to the epidemic of tuberculosis by 2030
[5]. Tuberculosis (TB) places a significant burden on the health system of South Africa, which
has the highest prevalence and incidence rates of all 22 countries with a high burden of TB
worldwide [6].
The impact of TB on HRQOL has been reported in a systematic literature review (Kastien-
Hilka et al 2016). This systematic review found that TB had a negative impact on patients’
HRQOL and overall wellbeing. The review further identified several factors associated with
HRQOL in TB which included socio-demographic (age, gender) and socio-economic (income,
education, housing, social security) characteristics, disease-related (symptoms) and therapy-
related (side effects, adverse events) factors, and psycho-social aspects (isolation and stigmati-
zation, psycho-social burden) [7–28]. Significant physical impairment caused by somatic
symptoms and consequences of TB has also been reported [14, 23, 27, 29].
Although TB treatment results in a significant improvement in HRQOL, especially in phys-
ical and psychological dimensions [9, 10, 13–15, 18, 19, 23, 24, 26] the treatment regimen can
be difficult for patients due to adverse drug reactions, the quantity of pills and treatment dura-
tion. This may have a significant impact on levels of adherence in this patient population.
There is also some published evidence to suggest that amongst TB patients, psycho-social bur-
den may have a greater impact than clinical symptoms. Specifically, anxiety and depression are
the most frequently reported mental disorders reported in TB patients [30, 31]. It is believed
that psychological distress may be caused by social stigmatization because of public miscon-
ception that a TB patient suffers from HIV co-infection [32, 33]. This association with HIV/
HRQOL in TB
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AIDS may lead to a perception of social isolation during TB treatment and further impacted
by the poor financial situation of many patients [27, 30, 34].
The impact of TB on HRQOL in South African populations was assessed in two studies
only, [18, 35, 36]. As most other published studies addressing HRQOL in TB patients, both
studies followed a cross-sectional study design. Data about longitudinal changes in HRQOL
which were assessed in South African TB patients were not available when our study was
planned and initiated. Since information on HRQOL contributes to efficient decision making,
product approval, pricing and reimbursement as well as health policy making, HRQOL data
will support the identification of sustainable health innovations in TB. A recognized reliable
and validated TB-specific HRQOL measure has not been available, however all relevant
HRQOL aspects of TB need to be captured to assess the achievement of the WHO´s End TB
Strategy pillars.
The aim of this research was to evaluate patient-reported HRQOL in pulmonary TB in
South Africa. The study sought to understand the overall impact of TB on the health status and
on single health domains identified in the WHO definition of health, including physical, men-
tal and social health aspects. The study addressed the impairment in HRQOL associated with
TB, prior to treatment and longitudinal changes in HRQOL over the course of a six-month
standard TB treatment.
Methods
A detailed description of the study design and methodology has been published previously
(Kastien-Hilka et al 2016). Briefly, the study followed an observational longitudinal design
including prospective, repeated measures of HRQOL per study participant.
Patient population and participant recruitment
Study participants were recruited between November 2014 and May 2015 at six selected pri-
mary health care clinics with the highest TB caseloads per month in Cape Town. Four of these
facilities are run by the local government, and two by the provincial government, and are
located in the Khayelitsha sub-district of the Cape Town Metro district. The sub-district has
the highest TB burden in Cape Town, based on latest available caseloads from 2012 provided
through the Western Cape Province. The study population comprised of patients diagnosed
with active pulmonary TB. TB patients who were 18 years or older and were not diagnosed
with TB before were eligible. Patients were excluded if they were diagnosed with multidrug-
resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), and/or had HIV co-
infection. Patients underwent HIV testing when diagnosed with TB before starting treatment.
The TB nurses of each study site provided to the study team access to the HIV test results dur-
ing the recruitment process to ensure a negative HIV status. HIV testing was not repeated dur-
ing the treatment and any change in the HIV status was therefore unknown. The eligibility
status of each patient was subject to verification by the nurse dedicated to TB patients of each
health facility. Based on a patient information document, eligible patients were informed
about the nature, purpose, potential risks and benefits of the study. Patients had the opportu-
nity to decline their participation or to withdraw from the study at any time point. Patients
who agreed to participate in the study signed a written informed consent.
Recruitment of new TB cases without HIV co-infection was difficult as a high proportion of
TB patients are also HIV co-infected in South Africa. In order to meet the sample size in the
pre-determined time frame, one additional clinic in a neighboring district was included in the
study.
HRQOL in TB
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Study procedures
Eligible participants received a six month standard TB treatment with rifampicin, isoniazid,
ethambutol and pyrazinamide. Standard treatment comprised the intensive treatment phase
over the first two months where all four antibiotic drugs were applied, and the continuous
treatment phase with isoniazid and rifampicin only over at least additional 4 month. This stan-
dard treatment was not influenced by the study design. HRQOL was evaluated during the
treatment course. The data collection regimen to monitor changes in HRQOL included five
different time points over the six-month treatment period: beginning of treatment (baseline)
and at follow-up visits after 4, 8, 16 weeks and after six-month treatment. The last data collec-
tion point at six months was selected as this time point represents the minimum treatment
time for standard TB treatment. Data collection at treatment start and after six-months of
treatment allowed the identification of HRQOL impairment caused by TB and any changes in
HRQOL due to treatment. Since standard treatment comprised two treatment phases, data
were collected at the switch between both phases (after 8 weeks) as well as in the middle of
each treatment phase (after 4 weeks and 16 weeks). Data collection started when TB patients
visited the study sites for treatment initiation; four HRQOL measures and one socio-demo-
graphic questionnaire were applied at baseline (treatment start). These four HRQOL measures
were re-applied at all follow up visits. All HRQOL measures were applied in English language
and have been validated for English for South Africa. No other languages or translations of
these measures were applied. Data were collected based on completion of paper questionnaires
during face-to-face interviews conducted by trained field workers. Field workers were trained
and quality of data was ensured based on a Standard Operating Procedure, and details were
published previously. Questionnaires were scanned by the field worker for any missing
responses during the interviews.
Study materials. The rationale for the selection of HRQOL measures has been described
previously (Kastien-Hilka et al 2016). Two generic (European Quality of Life 5 Dimensions 5
levels; EQ-5D-5L and Short-Form 12 items; SF-12), one disease-specific (St. George´s Respira-
tory Questionnaire; SGRQ) and one condition-specific (Hospital Anxiety and Depression
Scale; HADS) HRQOL measures were used. All HRQOL measures have been validated in TB
populations: SF-12 [18], EQ-5D-5L [37], SGRQ [38], and HADS [39].
EQ-5D-5L. EQ-5D-5L [40] is widely used as a utility index for estimating QALYs in cost-
effectiveness studies [40, 41]. It comprises five items/domains (5D) (Mobility, Self Care, Usual
Activities, Pain/Discomfort, and Anxiety/Depression) with each domain having five levels
(5L): no problems, slight problems, moderate problems, severe problems, and extreme prob-
lems; The EQ-5D-5L includes further one vertical visual analogue scale (VAS 20 cm). Index-
based values (utilities) are calculated from EQ-5D-5L by applying country-specific valuation
algorithms. No South African specific valuation algorithms were available. Therefore, algo-
rithms developed for the UK and for Zimbabwe, the only African country with an available
algorithm, were used in this study. The EQ-5D-5L utilities range from 0 to 1, with higher
scores indicating better health. A minimally important difference (MID) is only known for the
3 level version of EQ-5D, with a MID of 0.074 (range -0.011–0.140) and a MID of 7 for VAS
scores [42]. EQ-5D-5L has an improved sensitivity compared to the 3 level version and its
MID is also assumed for the 5 level version.
SF-12. Short-Form 12 (SF-12) is an abbreviated version of SF-36 containing 12 items rep-
resenting eight domains (physical functioning, role physical, bodily pain, general health, vital-
ity, social functioning, role emotional, and mental health) [41, 43]. Domains are aggregated
into composite summary scores, Physical Component Score (PCS-12) and Mental Component
Sore (MCS-12). Scoring ranges from 0 to 100 with greater scores representing better HRQOL.
HRQOL in TB
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A score between 47 and 53 reflects normal scores for both PCS and MCS based on US popula-
tion norms [44, 45]. No population norms for South Africa or other African countries are
available. A MID of at least 3 points has been suggested for the SF-36 [44] and can also be used
for SF-12v2 [46].
St. George´s Respiratory Questionnaire. St. George´s Respiratory Questionnaire
(SGRQ) is a disease-specific instrument designed to assess patients with respiratory tract and
immune system diseases, especially asthma, pulmonary diseases, and chronic obstructive dis-
ease [41, 47]. SGRQ comprises 50 items in three domains (Symptoms, Activity, and Impacts
on daily life). Scores are scaled from 0 to 100, with higher scores indicating worse HRQOL. A
MID for SGRQ is defined as an improvement of 4 points in the domain scores and the total
score [48].
Hospital Anxiety and Depression Scale. Hospital Anxiety and Depression Scale (HADS)
is a condition-specific instrument applied in psychology and psychiatry to detect states of anxi-
ety and depression [49]. HADS comprises 14 items in two domains, Anxiety domain and
Depression domain. The scores of each subscale range from 0–21 (8–10 mild, 11–14 moderate,
15–21 severe). A MID for HADS is not available from the developer. A MID of 1.5 points has
been estimated for chronic obstructive pulmonary disease (COPD), corresponding to a change
from baseline of 20% and informed by both anchor- and distribution-based methods [50].
Sample size
The primary endpoint was defined as change in mean score of PCS-12 between baseline and
six-month treatment. As SF-12 and SF-36 are comparable measures, sample size determina-
tion was based on the change in mean score of PCS-36 as reported by Walter [51]. We
assumed a 4.0 point change in PCS-12 mean score (higher than the MID of 3 points) between
baseline and visit 4 (six-months treatment) [45, 52], and a corresponding standard deviation
(SD) of 7.0 for the mean score after six-months treatment [45], resulting in a standardized
effect size of 0.57. Using the standardized effect size with a two-sided 5% level of significance
and a 95% power yielded in an estimated sample size of n = 80 participants. We estimated an
attrition rate of 20% resulting in a final sample size of n = 96 participants.
Ethics
The study adhered to the International Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human Use (ICH) guidelines, the Declaration
of Helsinki and South African Good Clinical Practice (GCP). The study was approved by the
institutional review commission of the Swiss Tropical and Public Health Institute in Basel,
Switzerland. Ethical approval was obtained from the ethical commission of North-West and
Central Switzerland (EKNZ) and the ethics committee of the University of Cape Town. City
Health of the City of Cape Town and the Western Cape Government of South Africa gave
institutional approval of the study.
Statistical analysis
Missing interviews were recorded as the absence of the study participant at the appointed
interview time frame. Missing data were recorded when the interviewed participant did not
complete HRQOL measures, or only insufficiently, hindering calculation of a domain or total
score. Significance testing (paired-samples t-test), multivariable analysis and repeated mea-
sures ANOVA were based on observations that contained all data points required for a specific
analysis.
HRQOL in TB
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All HRQOL responses were transferred to an excel-based database and all measures were
scored according to each measure´s instructions.
EQ-5D-5L utility scores were calculation based on valuation algorithms for the UK and
Zimbabwe, applying the EQ-5D calculator [40]. SF-12 component scores PCS-12 and MCS-12
as well as SGRQ domain and total score were calculated applying specific scoring software pro-
vided through the measure´s developer. HADS was scored based on an excel worksheet
according to the instructions in the HADS manual [53].
Interpretation of EQ-5D-5L domain scores and HADS Anxiety and Depression domains
were both based on categories: EQ-5D-5L on its five levels (no problems, slight problems,
moderate problems, severe problems, and extreme problems) and both HADS domains on
three levels (mild, moderate, severe). The SF-12 component scores and EQ-5D VAS were both
interpreted based on a range from 0 (worst health) to 100 (best health), the EQ-5D-5L utility
index on a range from 0 (worst health) to 1 (best health). The SGRQ domains and total score
were interpreted based on a range between 0 (best health) to 100 (worst health) and compared
to scores derived from a population with no history of respiratory disease [47].
Descriptive statistics were applied to socio-demographic data; further to all HRQOL data at
baseline and at all follow-up visits to understand the HRQOL impairment of TB patients.
Descriptive statistics were conducted including frequencies (N, N missing, %), central ten-
dency (mean, median), and confidence interval (set at 95%). Distribution of data was exam-
ined by standard deviation (SD), minimum and maximum values, and frequency plots.
Overall changes in HRQOL between baseline and six-month treatment (visit 4) were calcu-
lated as frequencies (%). Longitudinal changes were determined by the change in mean scores
between all follow-up visits and baseline. The change in mean scores was examined by paired-
samples t-test with a statistical significance (2-tailed) set a priori at P< 0.05. Changes in mean
scores in the intensive treatment phase (baseline to visit 2) were compared to changes in the
continuous treatment phase (visit 2 to visit 4) based on paired-samples t-test with a statistical
significance (2-tailed) set a priori at P < 0.05. The change in mean scores at each time point
from baseline was also compared to the reported minimally important difference (MID) for
each measure to understand if the longitudinal changes in HRQOL were clinically meaningful.
Paired-samples t-test was applied to examine the difference between changes in mean scores
and MID at a significance level of P< 0.05.
Differences in HRQOL mean scores among all HRQOL measures over time (baseline and
follow-up visit 1–4) were examined by repeated measures ANOVA. Bonferroni correction was
applied to repeated measures ANOVA for multiplicity of tests.
Responsiveness over time for each HRQOL was measured as an effect size partial eta
squared providing information of the effect of time on changes in HRQOL aspects. The time
effects were based on tests of within-subjects effects. When Mauchly´s test of sphericity was
not met (significance < 0.05), both partial eta squared and observed power were derived from
the Greenhouse-Geisser correction.
The impact of socio-demographic factors including age, gender, educational status and
work status were elaborated. At baseline univariable analysis was applied to understand which
factors might be associated with HRQOL, by using a cut off of P = 0.2. Resulting candidate fac-
tors were further assessed in multivariable models to understand the impact of socio-demo-
graphic factors over time (change from baseline to six month treatment (visit 4)). The
univariable and multivariable analysis included a general linear model and an analysis of vari-
ance (ANOVA). The time effect of socio-demographic factors based on an effect size partial
eta squared was further included by applying repeated measures ANOVA. Threshold values
for the effect size were derived from Cohen [54]: 0.1 was interpreted as small, 0.3 as medium,
0.5 as large and 0.8 as very large.
HRQOL in TB
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Robustness of the findings was assessed by sensitivity analyses by excluding HRQOL data
from visit 3. Further, the assessment of longitudinal changes of HRQOL over time including
baseline and all follow-up data as described above was repeated by excluding data from visit 3,
which was affected by a very low number of available observations. Results were checked for
consistency.
Results
In total, 131 eligible patients were recruited and agreed to participate in the study. Overall, 444
interviews were conducted over the duration of the study with questionnaires completed for
data analysis.
From 131 participants who had baseline interviews conducted, 84 (64%) participated in the
follow-up interview at visit 1, 85 (64%) participated at visit 2, 48 (36%) participated at visit 3
and 96 (70%) participated at visit 4. Only 20% of participants completed all HRQOL question-
naires at all time points during treatment as per protocol (Table 1).
During the course of treatment a total of 47, 46, 83, and 35 patients did not participate in
follow-up interviews 1 to 4, respectively. In the majority of cases the reason for absence of par-
ticipants was unknown. Of those participants who attended an appointment during the study
period, none refused to participate in the interview. However, four patients were unable to par-
ticipate at follow-up interviews as they had been transferred to a different hospital not included
in this study and one patient received a custodial sentence. The lowest attendance rate to inter-
views was observed after 16 weeks of treatment (visit 3). The reasons why participants did not
attend their clinic appointments, and hence the low response rate, was unknown. Although
Direct Observed Treatment (DOT) is officially implemented to ensure patient compliance in
South Africa, patients did not take medication under DOT; patients only visited the clinics
once a month to collect their medication in advance. The interviews for HRQOL evaluation
were taken, when a patient planned to visit the clinic for medication collection. When a patient
did not visit the clinic at the scheduled medication collection date, the patient collected the
medication at a different day. As communication to patients in this socio-demographic envi-
ronment was very restricted due to the availability of mobile phones, a new interview appoint-
ment could only be re-scheduled in some cases.
In total, nine questionnaires were not completed by patients during the fieldwork. Whilst
completing the sections on HRQOL measures, two patients did not answer the socio-demo-
graphic questionnaire, but all HRQOL measures; these two patients were still included in the
data analysis. One of each measure was not answered during the data collection: SF-12 at base-
line and at visit 1; EQ-5-D-5L at baseline and at visit 4; SGRQ at baseline, and HADS visit 1
and visit 2.
Description of the study population
Table 2 describes the study population. Of 131 study participants, two participants did not pro-
vide information on socio-demographic data; 129 participants were included in the descrip-
tion of the study population. Study participants who provided socio-demographic data
(n = 129) comprised 64% (n = 82) men and 36% (n = 47) women, age ranged from 18 years to
80 years, with the majority of participants being between 20 and 40 years and with a mean age
of 36 years. The majority of participants were black (90%), living alone (i.e. not married nor
co-habitation; 82%), and high school education attainment (68%). The majority of the study
participants (73%) were unemployed, students or pensioners. Only 21% of the study partici-
pants were aware about existing co-morbidities impacting their health, most of them reporting
to be diagnosed with other respiratory diseases or diabetes.
HRQOL in TB
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Table 1. Overview of interviews taken per study site.
Data Collection Point Total Number
Interviews
Number of interviews
Study site
1
Study site
2
Study site
3
Study site
4
Study site
5
Study site
6
Study site
7
Baseline (treatment start) 131 54 9 18 9 8 13 20
Visit 1 (4 weeks post treatment
start
84 31 8 17 5 6 3 14
Visit 2 (8 weeks post treatment
start
85 34 8 18 2 5 9 9
Visit 3 (16 weeks post treatment
start
48 7 10 17 1 1 7 5
Visit 4 (24 weeks post treatment
start
96 41 9 17 3 2 9 15
Total 444
https://doi.org/10.1371/journal.pone.0174605.t001
Table 2. Socio-demographic description of study population.
Socio-demographic Factors Study population
N % N missing
Gender 129 2
Male 82 63.6
Female 47 36.4
Age 129 2
Mean age 35.8
Median age 31
Min 18
Max 80
Age groups 129 2
18–30 60 46.5
31–50 46 35.7
>51 23 17.8
Ethnicity 129 2
Black 116 89.9
Other 13 10.1
Marital status 129 2
Single/never married/divorced/separated/widowed 103 81.7
Married/co-habitation 23 18.3
Education 129 2
Primary school 30 23.8
High school 86 68.3
College or university 10 7.9
Employment status 128 3
Employed/self-employed/own business 34 26.6
Unemployed/student/pensioner 94 73.4
Co-morbidities 27 104
Other respiratory diseases 13 48.1
Diabetes 13 48.1
Cancers None reported
Cardio-vascular diseases 1 3.7
Unknown co-morbidities None reported
https://doi.org/10.1371/journal.pone.0174605.t002
HRQOL in TB
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The characteristics of the full study population were similar to the characteristics of those
patients who provided information at the last visit, after six months of treatment.
HRQOL impairment of TB patients at treatment start
Based on each measure´s score interpretation the HRQOL of the study participants was
impaired in all physical, mental and psycho-social health domains at treatment start (baseline)
(Table 3).
Development of HRQOL during TB treatment
All scores of HRQOL domains improved during the course of standard TB treatment, and
over the period of the study (Fig 1). These changes were statistically significant. The largest
improvement was observed in domains relating to mental health (increase in mean score
between baseline and six month treatment of 59% - 95%), with the highest change observed in
the HADS Anxiety and Depression domains, followed by improvements in the physical health
domains and the social health domains. The primary endpoint defined as change in mean
score of PCS-12 between baseline and six months from treatment initiation (visit 4) showed a
change of 20 points (from 35.93 to 55.21) which was statistically significant (P <0.005) (Fig 2).
The change in mean score was also greater than the published MID threshold to be considered
clinically meaningful (Fig 3)
The change in HRQOL over time was statistically significant based on average mean scores.
The change was greater than published MID thresholds for each HRQOL measure and thereby
clinically meaningful. The MCS-12 mean score showed a greater relative improvement by
+67% over six month treatment than the PCS-12 (+54%). Both component scores changed to
Table 3. Baseline impairment of HRQOL in TB patients at treatment start.
HRQOL measure HRQOL domaim N (%) Mean score (SD) 95% Confidence Interval Median Range N missing (%)
Min Max
SF12 PCS-12 129 35.930 (8.321) 34.477–37.376 33.990 16.100 57.090 2
MCS-12 129 36.011 (11.487) 34.013–38.015 35.840 11.690 68.900 2
EQ-5D Mobility 129 2.442 (1.117) 2.247–2.637 3.000 1.000 5.000 2
Self Care 129 2.434 (1.131) 2.237–2.631 3.000 1.000 5.000 2
Usual Activites 129 2.558 (1.224) 2.345–2.771 3.000 1.000 5.000 2
Pain&Discomfort 129 2.496 (1.098) 2.305–2.687 3.000 1.000 5.000 2
Anxiety&Depression 129 2.566 (1.224) 2.353–2.779 2.000 1.000 5.000 2
Utility Index (UK) 129 0.505 (0.328) 0.448–0.562 0.546 -0.594 1.000 2
Utility Index (Zim) 129 0.620 (0.203) 0.584–0.655 0.621 -0.145 0.900 2
VAS score 129 54.512 (18.066) 51.364–57.659 50.000 10.000 100.000 2
SGRQ Symptoms 126 41.333 (33.803) 35.349–47.317 45.419 0.000 100.000 5
Activities 126 70.087 (30.868) 64.622–75.522 79.671 0.000 100.00 5
Impact 126 61.542 (25.638) 57.003–66.081 66.798 0.000 100.00 5
Total score 126 61.134 (23.045) 57.055–65.214 66.366 0.000 92.643 5
HADS Anxiety 131 11.504 (5.772) 10.506–12.502 12.000 0.000 21.000 0
Depression 131 12.092 (6.237) 11.014–13.170 13.000 0.000 21.000 0
SF-12: 0 to 100 (= best HRQOL); EQ-5D domains: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = extreme
problems. EQ-5D total index 0 to 1 (best HRQOL); EQ-5D VAS: 0 = worst health to 100 (= best health); SGRQ 0 to 100 (= worst health); HADS: normal (0–
7) mild (8–10) moderate (11–14) severe (15–21)
https://doi.org/10.1371/journal.pone.0174605.t003
HRQOL in TB
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a value of 55 points for PCS-12 and 60 points for MCS-12 and these values were above U.S.
population norms (47 points for PCS-12 and 53 points for MCS-12) [44, 45]. All EQ-5D-5L
average domain scores changed from an average state of “moderate health problems” to a state
reporting “no problems” (+57–59%). The total index of EQ-5D reflected the same change as
was observed on domain level. The total index calculated using the UK valuation algorithm
changed by +94%. However, the total index value based on the Zimbabwe valuation algorithm
changed by only +44%. The health status of the TB patients measured with the EQ-5D VAS
changed by +78%.
The three SGRQ domains showed the greatest change in the physical symptoms domain
with +90% improvement. Both domains of HADS (anxiety and depression) changed by +95%
from a state of “moderate problems” to a state of reporting “no problems”.
Fig 1. The development of HRQOL over six-month treatment.
https://doi.org/10.1371/journal.pone.0174605.g001
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The changes in mean scores during the intensive treatment phase were significant and
(baseline to visit 2) higher than during the continuous treatment phase (visit 2 to visit 4). The
changes in mean scores of the SGRQ Activities and Impact domains as well as in the SGRQ
total score were non-significant during the continuous phase (S1 Table).
Changes in mean scores increased constantly until six month treatment for SF-12, EQ-5D
VAS and HADS. The change in EQ-5D and SGRQ mean scores also increased significantly
but with a peak after 16 weeks of treatment (visit 3) and changes in mean scores decreased
until six month of treatment. Repeated measures ANOVA confirmed that the overall improve-
ment in all HRQOL measures was associated with a statistically significant time effect ranging
between 58% and 85%, with the highest effect observed on the health status (EQ-5D VAS) (S2
Table). Sensitivity analysis applied to repeated measure by leaving out data from visit 3 con-
firmed the robustness of the findings (S2 Table).
The Influence of socio-demographic factors on baseline HRQOL and
longitudinal changes in HRQOL
Significant results from the univariable analysis including the socio-demographic factors
gender, age, educational level and work status were further assessed in a multivariable model.
The univariable analysis showed that HRQOL at baseline was more impacted in older
patients with low educational background and without work. Age and education were signifi-
cant factors in mental health domains, with younger patients with higher education reporting
better HRQOL; work status played no major role in the mental health. With exception of
MCS-12, gender played no role in HRQOL. Only in MCS-12 women reported a lower
HRQOL than men. The multivariable model confirmed that younger patients (SGRQ Impacts
domain, SGRQ total score, HADS Anxiety and Depression domains) with higher education
(EQ-5D total index, HADS Anxiety and Depression domains) and with work (EQ-5D total
index, SGRQ Symptoms domain) had a better HRQOL at baseline. These effects were only
seen at baseline for all HRQOL measures (Table 4) and not after six months of treatment.
Fig 2. Histograms of PCS-12 at baseline and after six-month treatment.
https://doi.org/10.1371/journal.pone.0174605.g002
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PCS-12 mean scores at six months were not significantly different for gender, age, educational
background and employment status.
Results from the repeated measures ANOVA showed no statistically significant effect of
gender and age on the overall HRQOL improvement. However, education and work status
showed significant effects. Patients with higher education and with work reported better
HRQOL. Education (df = 1.000, F = 6.632, P = 0.012, eta = 0.074) and work status (df = 1.000,
F = 7.789, P = 0.007, eta = 0.086) had a statistically significant but small effect on the HRQOL
improvement with regard to PCS-12 (physical health). Similar effects were observed for the
Fig 3. Change in HRQOL over six-month treatment.
https://doi.org/10.1371/journal.pone.0174605.g003
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EQ5D utility indices (UK valuation algorithm: education df = 1.000, F = 7.071, P = 0.009,
eta = 0.078; work status df = 1.000, F = 7.799, P = 0.006, eta = 0.085); Zimbabwe valuation algo-
rithm: education df = 1.000, F = 6.821, P = 0.011, eta = 0.075; work status df = 1.000, F = 7.438,
P = 0.008, eta = 0.081). Further, work status showed a statistically significant (df 1.000,
F = 7.654, P = 0.007, eta = 0.081) but small effect on the overall improvement of the HRQOL
domain SGRQ Symptoms (physical health) (S3 Table).
Discussion
The increasing prevalence of non-communicable diseases (NCDs) and communicable diseases
such as TB in South Africa leads to an increased pressure on healthcare resources. More
importantly, from the patient perspective it also has an impact on the general well-being and
HRQOL of patients.
This study was designed to evaluate changes in HRQOL in South African patients recently
diagnosed with TB (without HIV co-infection) during the course of standard TB treatment
over a six-month period. Two generic HRQOL measures (SF-12 and EQ-5D), a disease-spe-
cific measure (SGRQ) for respiratory diseases and a condition-specific measure for anxiety
and depression, the HADS were used to assess HRQOL [55]. These four HRQOL measure cap-
tured relevant health aspects of TB in the physical, mental and psychosocial domains. The
study population was recruited from the Cape Town district Khayelitsha, a socio-economically
disadvantaged area. The majority of TB patients were in the productive years of their lives.
However, more than 70% were not in employment. At the start of treatment, HRQOL
domains and total scores on all measures indicated significant impairment in HRQOL. The
results demonstrate that HRQOL improved significantly over treatment time, with the greatest
improvement observed during the intensive phase of treatment and with greatest improve-
ment in mental health domains.
Socio-demographic predictors for HRQOL at baseline included age, educational back-
ground and work status. Younger TB patients with a higher education, and who were in
Table 4. Associations between HRQOL and socio-demographic factors at baseline.
EQ-5D utility
index UK
EQ-5D utility index
Zimbabwe
SGRQ
Symptoms
SGRQ
Impacts
SGRQ
total
HADS
Anxiety
HADS
Depression
Age
P value* - 0.047 - 0.046 0.020 0.017 0.029
18–30 years - 0.655 - 56.959 55.998 11.462 11.179
31–50 years - 0.615 - 63.373 63.381 11.297 12.703
>51 years - 0.501 - 75.168 74.813 15.588 15.824
Education
P value* 0.015 0.015 - - - 0.010 0.044
Primary school 0.340 0.516 - - - 14.526 15.158
High school 0.528 0.629 - - - 11.862 12.154
College or university 0.745 0.766 - - - 7.286 9.000
Work status
P value* 0.008 0.010 0.020 - - - -
Employed, self-employed,
own business
0.669 0.713 26.917 - - - -
Unemployed, student,
pensioner
0.444 0.578 46.399 - - - -
* P values are for differences in baseline HRQOL between categories of socio-demographic factors.
https://doi.org/10.1371/journal.pone.0174605.t004
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employment reported better HRQOL at baseline. A significant effect of educational back-
ground and work status has been reported before [56, 57]. It can be assumed that a better edu-
cation increases the chances for work and financial security which might have a positive effect
on HRQOL by improved self-care, improved social interactions, less psycho-social distress
and less financial burden. Gender differences showed no significant effect on most HRQOL
domains at baseline; only in the MCS-12 women reported a lower HRQOL than men. These
effects of age, education and work status were not found after six months of treatment.
Gender and age were no predictors for positive changes in HRQOL over the treatment
course. A recent study from Louw et al 2016 confirmed our findings of a non-effect of gender
and age on HRQOL in TB patients after six month treatment in other Provinces in South
Africa [58]. However, the same study reported that higher education was significantly associ-
ated with an improvement in mental health (MCS-12) after six month of treatment. Our study
confirmed the effect of education on mental health aspects (anxiety and depression) only at
baseline.
All changes over treatment time were statistically significant and were also clinically mean-
ingful. The greatest improvements in physical health were measured with the respiratory-spe-
cific measure SGRQ. The primary endpoint defined as overall change in PCS-12 did not
reflect the greatest improvements. It can be assumed that the Symptoms domain of SGRQ cap-
tures physical impairment due to TB in more detail and thereby being more sensitive to any
changes in HRQOL than generic measures such as SF-12 and EQ-5D.
The study results revealed that the greatest improvement in all HRQOL domains was seen
in the mental health of TB patients. The condition-specific HADS measure showed a similar
impact on mental health at treatment start as reported from a study in Pakistan [59]. These
results confirm previous findings suggesting that mental health is an important aspect in the
treatment of TB. About 46–80% of TB patients in South Africa report common mental disor-
ders [32, 35]. This psychological distress is associated with physiological TB symptoms, per-
ceived health status, adverse events through anti-TB treatment and treatment outcome [30].
Furthermore, psychological distress may be caused by social stigmatization (HIV co-infection)
followed by social isolation during TB treatment and impacted financial situation including
fear of dying and disease transmission [27, 30–32, 34]. Special focus on reduction of stigmati-
zation should be given in the management of TB to reduce the psychological distress [60]. This
may suggest that patients perceive a positive outlook suffering less from the depression and
anxiety associated with TB in South Africa. This again, is something that should be considered
in the light of non-adherence. Inclusion of psychological support and treatment of mental dis-
orders in the management of TB should be considered as well as interventions to reduce the
stigmatization related to TB to improve the overall treatment outcome.
The physical and mental impairment seen in the South African patient population in this
study is confirmed by studies in other countries applying the same HRQOL measures. The
generic SF-12 measure indicated at treatment start a similar impairment in both the PCS-12
and MCS-12 with a score of 36, presenting defective physical functioning and a high risk for
depression. A similar HRQOL impairment was reported in a study with TB affected immi-
grants in the UK [61] and from a study in Yemen [62]. Other studies which measured
HRQOL by SF-36 or SF-12 in TB patients reported higher scores between 40 and 61 and
thereby a better HRQOL at treatment start in Canada, Uganda, and Malaysia [24, 25, 37, 45,
52, 63]. Measuring the HRQOL in TB with the generic measure EQ-5D, our TB patients in
South Africa reported a more impaired HRQOL and health status than in other countries
(Malaysia, the UK, Canada) [14, 37, 61]. The same effect was found with the respiratory-spe-
cific measure SGRQ showing that our study population had a more impacted HRQOL than
TB patients from Indonesia [64]. The SGRQ total score still showed some impairment with a
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score of 14 compared to a value of 5–7 reported by people from Spain with no respiratory his-
tory [47].
The phenomenon of an initial worsening in HRQOL after treatment start reported previ-
ously could not be confirmed by our observations [65]. Our study confirmed that the greatest
improvement in HRQOL was seen during the intensive phase and this observation was
reported before [9, 14, 15, 19, 26]. It is expected that monitoring of adherence during this treat-
ment phase should be implemented to ensure that patients continue with their medication
regime as many may perceive this improvement in their HRQOL as a sign of ‘cure’ and there-
fore no need to continue with their medication.
Comparing the results from the EQ-5D VAS and EQ-5D utility index based on value sets
from UK with value sets from Zimbabwe clearly showed some cultural differences in HRQOL
changes over time and its interpretation, and highlight the need for specific population norms
for South Africa. The EQ-5D VAS reached a higher value of 97 than that of the general popula-
tion in the UK of 82.5 and in Zimbabwe of 79.8 [66]. At baseline the utility index derived from
the UK value set was by 0.115 points lower than the utility index derived from the Zimbabwean
value set and this difference was greater than the MID for EQ-5D-5L. This is critically impor-
tant in the context of the increasing request for cost-effectiveness analysis (CEA) from health
systems in the allocation of resources. The EQ-5D is the preferred instrument to estimate pop-
ulation-based utilities for the calculation of quality-adjusted life years (QALYs) to provide a
cost per QALY outcome in CEA. In 2013, the South African Department of Health published
the Guidelines for Pharmacoeconomic Submissions which requests the use of QALYs for CEA
[67]. The development towards pharmacoeconomic evaluations in South Africa for efficient
decision making would require data acquisition to establish South African population norms
for the EQ-5D.
Limitations
This study had several limitations. HRQOL was only evaluated in patients with newly diag-
nosed pulmonary TB and patients with other forms of TB including multi-drug resistance
(MDR-)TB were not included. If MDR-TB was diagnosed during treatment monitoring the
patient had to change the treatment and was excluded from the study. If and at which time
point drug susceptibility testing was performed at the different study sites was unknown. Fur-
thermore, this study did not include testing of drug intolerance or drug sensitivity and the
impact of drug intolerance and drug sensitivity on HRQOL was not known.
Our sample size was difficult to reach in one restricted district due to the low number of TB
patients without HIV co-infection, as well as due to time and resource limitations in this study.
In South Africa the high majority of TB patients are HIV co-infected; this study did exclude
HIV co-infection to understand the isolated TB impact on HRQOL. Further, this study did not
include a comparison or control group from the general population, for time and resource lim-
itations. Our study did not apply a mixed method approach and was limited to a quantitative
approach; patient perspectives about TB in a South African cultural background were not qual-
itatively assessed. Such data might have enriched the quantitative findings for HRQOL in this
study. HRQOL was only assessed in a specific district of the Western Cape Province with a spe-
cific socio-demographic and –economic situation. Results from this study may not be general-
izable to the rest of the South African population which is very diverse. Receiving treatment for
their condition may have put an increased economic pressure on these participants as they
may have been unable to take on work or consider their working options due to the travel dis-
tance between a health clinic they get the treatment from and workplace, but also due to the
disease induced worsening of their physical condition [12, 27, 29].
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Additionally, there is an increased risk of tuberculosis when diagnosed with diabetes [68],
therefore we expected diabetes to be a major co-morbidity in our TB patients. We included
questions about NCDs in our study, however it was apparent that only a small portion of TB
patients were aware of any co-morbidity they may have, including diabetes. We assume that
other health issues are unknown to a majority of TB patients. These unknown co-morbidities
are assumed to have an additional impact on the HRQOL in TB patients at baseline which we
could not distinguish.
Conclusions
TB negatively impacts the HRQOL of patients, with specific impairment reported in physical,
mental and psycho-social health aspects, however with treatment HRQOL improves signifi-
cantly. Different aspects of health (HRQOL domains) are impacted differently and it would
appear that the rate of improvement in each domain may also be different. HRQOL reveals dif-
ferent outcomes depending on the type of measure applied and depending on the cultural
background and the study setting, making comparison of HRQOL outcomes difficult. Generic
HRQOL PROs may not adequately capture all relevant aspects of TB, and thus a disease-spe-
cific HRQOL measure is required. This study also demonstrates the need for an integrative
understanding of TB with HRQOL as core element to inform gaps in current TB management.
Improvements in the management of TB following an integrative patient-centred approach
will contribute towards meeting the UN SDG3 target and will support the End TB strategy of
the WHO.
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